Detalles de la búsqueda
1.
Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19.
Front Immunol
; 15: 1330178, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38694503
2.
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron.
Open Forum Infect Dis
; 10(6): ofad279, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37351456
Resultados
1 -
2
de 2
1
Próxima >
>>